fda shortage tirzepatide update says of GLP-1 drug is over Tirzepatide Update: On December 19th

As the eligible patient population in the UK is high, reimbursement is also subject to conditions, such as achieving weight loss within a certain period of time

These came from different trials, with different durations, dose-titration schedules, and patient populations they were not compared head-to-head

You have the right to appealand appeals work

When accompanied by sustainable lifestyle changes, weight loss achieved with medication can be maintained even after discontinuing the drug, although individual results may vary

Both conversations are important

In summary, you can expect: regular clinic visits and blood tests (IGF-1 and others) every few months initially